Dosing Begins in Phase 1 Trial of STRO-001, Potential Lymphoma and Multiple Myeloma Therapy
News
A Phase 1 study of Sutro Biopharma’s STRO-001 treatment candidate for non-Hodgkin’s lymphoma and multiple myeloma has begun dosing patients, the company announced. STRO-001 is an antibody drug conjugate (ADC) that targets ... Read more